U.S. markets closed

ASLAN Pharmaceuticals Limited (ASLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8800+0.0100 (+0.53%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close1.8700
Open1.8700
Bid1.8600 x 1100
Ask1.9400 x 4000
Day's Range1.8558 - 1.9082
52 Week Range0.8300 - 8.1800
Volume58,465
Avg. Volume260,365
Market Cap71.423M
Beta (5Y Monthly)2.72
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

    SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available from November 23, 2020 in the Investor Relations section of ASLAN’s website at www.aslanpharma.com. The replay will be available for 30 days. ASLAN will be participating in 1x1 meetings on 30 November to 3 December 2020, meetings may be requested exclusively via Piper Sandler.Media and IR contactsEmma Thompson Spurwing Communications Tel: +65 6751 2021 Email: ASLAN@spurwingcomms.com Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com    About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.Forward looking statementsThis release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialise ASLAN004 and ASLAN003; the safety and efficacy of ASLAN004 and ASLAN003; the Company’s plans and expected timing with respect to clinical trials and clinical trial results for ASLAN004 and ASLAN003; the potential for ASLAN004 to deliver a best-in-disease treatment for people with atopic dermatitis; the potential for ASLAN003 to have a best in class profile as a potent oral DHODH inhibitor targeting autoimmune indications; the potential for ASLAN003 to be a treatment for COVID-19 and other viral infections; and the scale of the unmet need in atopic dermatitis. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company’s business and the global economy; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 16, 2020.  All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

  • GlobeNewswire

    ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

    SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2020 and provided an update on its clinical activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “The third quarter saw great progress being made on multiple fronts for ASLAN. We resumed our multiple ascending dose (MAD) study of ASLAN004 following the lifting of COVID-19 restrictions and quickly completed recruitment of the second cohort, which we believe is an indicator of the scale of the unmet need we aim to address in atopic dermatitis. Recruitment of the third cohort is underway from sites in the US, Australia and Singapore, and we expect to announce new, unblinded data in early 2021. The move of our primary listing to the US is now complete and aligned with our plans to initiate a global Phase 2b study in atopic dermatitis in 2021 and new clinical studies of ASLAN003 in autoimmune disease.” Third quarter 2020 and recent business highlightsClinical development      ASLAN004 * Investigational New Drug application submitted to the US Food and Drug Administration became effective and Clinical Trial Notification cleared by the Therapeutics Goods Administration in Australia. * Seven new clinical sites opened in the US and Australia designed to support recruitment of patients into the ongoing MAD study. * Initiated recruitment of patients into third dose cohort in October at sites in the US, Australia and Singapore following successful safety review of second cohort that resumed recruitment in August. ASLAN004 was found to be well tolerated at 400mg and the Data Monitoring Committee (DMC) recommend that the MAD study continue as planned.     ASLAN003 * Announced plans to develop ASLAN003, ASLAN’s next generation inhibitor of dihydroorotate dehydrogenase (DHODH), in autoimmune conditions, such as multiple sclerosis, following review of the data generated on ASLAN003 and discussions with experts in the field. ASLAN believes that ASLAN003 has a potential best in class profile as a potent oral DHODH inhibitor targeting autoimmune indications. * Appointed renowned neurologist Professor Gavin Giovannoni, Chair of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, as a scientific advisor to the Company. ASLAN will work with Professor Giovannoni on the clinical development plan of ASLAN003. * Based on previous observations of anti-viral activity against Dengue and Zika viruses, ASLAN recently determined that ASLAN003 has nanomolar potency against SARS-CoV-2 in Vero E6 cells (EC50 = 1.4 nM) and is assessing the potential of ASLAN003 as a treatment for COVID-19 and other viral infections.Corporate updates * Appointed Dr Kenneth Kobayashi as Chief Medical Officer. Dr Kobayashi most recently worked at Dermira, where he was responsible for the development of lebrikizumab, and previously held roles at Novartis and LEO Pharma. Dr Kobayashi brings more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. * Movement of primary listing to the Nasdaq Global Market and delisting from the Taipei Exchange completed in August. ASLAN has retained its listing of American Depositary Shares (ADS) on Nasdaq in the United States.Anticipated upcoming milestones * Interim, unblinded data on ASLAN004 from the 3 dose cohorts (up to 24 patients) and initiation of the expansion cohort (an additional 18 patients) expected in early 2021. * Completion of MAD clinical study of ASLAN004 in moderate-to-severe atopic dermatitis (AD) patients expected in 1H 2021. * Initiation of Phase 2b study of ASLAN004 for AD expected in 2021.          Third quarter 2020 financial highlights * Cash used in operations for the third quarter of 2020 was US$2.6 million compared to US$7.0 million in the same period in 2019. * Research and development expenses were US$2.2 million in the third quarter of 2020 compared to US$4.1 million in the third quarter of 2019. The decrease was driven by the completion of clinical studies related to varlitinib. * General and administrative expenses were US$1.3 million in the third quarter of 2020 compared to US$1.1 million in the third quarter of 2019. * Net loss for the third quarter of 2020 was US$3.5 million compared to a net loss of US$5.2 million for the third quarter of 2019. * Cash, cash equivalents and short-term investments totaled US$12.1 million as of September 30, 2020 (this includes US$0.9 million of cash received in connection with the ADS scheme that will be paid to our depository agent in 4Q 2020) compared to US$22.2 million as of 31 December 2019. Weighted average ADS outstanding for the third quarter of 2020 was 38.0 million (or equivalent) compared to 32.0 million (or equivalent) for the third quarter of 2019. One ADS is the equivalent of five ordinary shares.             ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEET1 (in US dollars)  December 31, 2019 (audited) September 30, 2020 (unaudited) ASSETS           CURRENT ASSETS     Cash and cash equivalents $22,203,031  $12,060,285  Prepayments  68,923   341,979        Total current assets  22,271,954   12,402,264        NON-CURRENT ASSETS     Financial assets at fair value through profit or loss  68,256   59,002  Financial assets at fair value through other comprehensive income  132,160   57,829  Property, plant and equipment  38,333   19,942  Right-of-use assets  727,866   528,751  Intangible assets  2,845   402  Refundable deposits  108,076   108,542        Total non-current assets  1,077,536   774,468        TOTAL ASSETS $           23,349,490  $           13,176,732        LIABILITIES AND EQUITY           CURRENT LIABILITIES     Trade payables $1,871,843  $2,248,833  Other payables  3,246,842   2,575,322  Lease Liabilities - current  264,543   207,212  Other current liabilities  -   918,150        Total current liabilities  5,383,228   5,949,517        NON-CURRENT LIABILITIES     Financial liabilities at fair value through profit or loss  262,350   262,350  Long-term borrowings  17,065,305   17,499,074  Long-term borrowing from related parties  566,176   603,704  Lease liabilities - non-current  490,835   351,935  Other non-current liabilities  184,870   253,596        Total non-current liabilities  18,569,536   18,970,659        Total liabilities  23,952,764   24,920,176        EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY     Ordinary shares  61,366,844   61,366,844  Capital surplus  116,495,710   116,495,710  Accumulated deficits  (179,484,825)  (189,966,716) Other reserves  (55,084)  (129,415)       Total equity attributable to stockholders of the Company  (1,677,355)  (12,233,577)       NON-CONTROLLING INTERESTS  1,074,081   490,133        Total equity  (603,274)  (11,743,444)       TOTAL LIABILITIES AND EQUITY $           23,349,490  $           13,176,732            ASLAN Pharmaceuticals Limited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)1 (in US dollars, unaudited)   For the Three Months Ended September 30 For the Nine Months Ended September 30    2019   2020   2019   2020  NET REVENUE $-  $-  $3,000,000  $-            COST OF REVENUE  -   -   (425,000)  -            GROSS PROFIT  -   -   2,575,000   -            OPERATING EXPENSES         General and administrative expenses  (1,111,697)  (1,347,487)  (5,253,502)  (4,135,910) Research and development expenses  (4,145,827)  (2,185,322)  (13,883,992)  (6,432,497) Total operating expenses  (5,257,524)  (3,532,809)  (19,137,494)  (10,568,407)           LOSS FROM OPERATIONS  (5,257,524)  (3,532,809)  (16,562,494)  (10,568,407)           NON-OPERATING INCOME AND EXPENSES         Interest income  206   222   144,417   438  Other gains and losses  199,054   (199,005)  (38,290)  192,430  Finance costs  (206,596)  (243,516)  (608,502)  (921,153) Total non-operating income and expenses  (7,336)  (442,299)  (502,375)  (728,285)           LOSS BEFORE INCOME TAX  (5,264,860)  (3,975,108)  (17,064,869)  (11,296,692)           INCOME TAX EXPENSE  79,710   230,853   (395,290)  230,853            NET LOSS FOR THE PERIOD  (5,185,150)  (3,744,255)  (17,460,159)  (11,065,839)           OTHER COMPREHENSIVE LOSS         Items that will not be reclassified subsequently to profit or loss:         Unrealized loss on investments in equity instruments at fair value through other comprehensive income  (9,046)  -   (9,046)  (74,331) TOTAL COMPREHENSIVE LOSS FOR THE PERIOD $(5,194,196) $(3,744,255) $(17,469,205) $(11,140,170)           NET LOSS ATTRIBUTABLE TO:         Stockholders of the Company $(5,194,196) $(3,476,002) $(17,460,159) $(10,481,891) Non-controlling interests  -   (268,253)  -   (583,948)   $(5,194,196) $(3,744,255) $(17,460,159) $(11,065,839)           TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO:         Stockholders of the Company $(5,194,196) $(3,476,002) $(17,469,205) $(10,556,222) Non-controlling interests  -   (268,253)  -   (583,948)   $(5,194,196) $(3,744,255) $(17,469,205) $(11,140,170)           LOSS PER SHARE         Basic and diluted $(0.03) $(0.02) $(0.11) $(0.06) Weighed-avg. shares outstanding (in thousands)  160,249   189,955   160,249   189,955  1 Financial Statements in US dollars are prepared by the Company and are unaudited as of September 30, 2020. Media and IR contacts Emma Thompson Spurwing Communications Tel: +65 6751 2021 Email: ASLAN@spurwingcomms.com Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.Forward looking statementsThis release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialise ASLAN004 and ASLAN003; the safety and efficacy of ASLAN004 and ASLAN003; the Company’s plans and expected timing with respect to clinical trials and clinical trial results for ASLAN004 and ASLAN003; the potential for ASLAN004 to deliver a best-in-disease treatment for people with atopic dermatitis; the potential for ASLAN003 to have a best in class profile as a potent oral DHODH inhibitor targeting autoimmune indications; the potential for ASLAN003 to be a treatment for COVID-19 and other viral infections; and the scale of the unmet need in atopic dermatitis. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company’s business and the global economy; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 16, 2020.All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

  • GlobeNewswire

    ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial

    \--   ASLAN has initiated recruitment of patients into third dose cohort at sites in the US, Australia and Singapore following successful safety review of second cohort \--   ASLAN004 found to be well tolerated at 400mg dose, third cohort will test 600mg doseSINGAPORE, Oct. 22, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that the Data Monitoring Committee (DMC) has completed its planned safety data review of the second dose cohort of its clinical trial of ASLAN004 in moderate to severe atopic dermatitis (AD) patients. ASLAN004 was found to be well tolerated at 400mg and the DMC has recommended that the multiple ascending dose (MAD) clinical study continue as planned.ASLAN has now initiated recruitment into the third, highest dose (600mg) cohort of the randomised, double blind, placebo-controlled MAD study. A total of eight patients will be recruited from clinical sites in Singapore, the US and Australia. ASLAN expects to report interim, unblinded data from all three dose escalation cohorts in early 2021.Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: “Importantly, ASLAN004 continues to be well tolerated in the patients treated in the study to date and no discontinuations of treatment related to study drug have been observed. Following the lifting of recruitment restrictions associated with COVID-19 that had previously delayed the study, we were pleased to note that the second dose cohort enrolled all eight patients in around three weeks at two clinical sites. For the third dose cohort, we will be recruiting patients from up to nine sites, having activated new sites in Australia and the US. We believe that ASLAN004 has the potential to be a best-in-disease treatment for patients with AD and look forward to reporting further data and firming up our plans to initiate a Phase 2b study in 2021.” The Phase 1 study is evaluating three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously and will include a fourth (expansion) cohort. Each dose cohort contains up to six patients on ASLAN004 and two patients on placebo, and the expansion cohort will contain at least 12 patients on ASLAN004 and at least six patients on placebo. Patients are dosed weekly for eight weeks to determine safety and tolerability as well as a number of secondary efficacy outcome measures.ASLAN004 is a first-in-class monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signalling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of AD, such as redness and itching of the skin.Media and IR contactsEmma Thompson Spurwing Communications Tel: +65 6751 2021 Email: ASLAN@spurwingcomms.com Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.Forward looking statementsThis release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy, the Company’s plans to develop and commercialise ASLAN004, the safety and efficacy of ASLAN004, the potential for ASLAN004 to deliver a best-in-disease treatment for people with atopic dermatitis, and the Company’s plans and expected timing with respect to enrolment in its clinical trials for ASLAN004 and clinical trial results for ASLAN004. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company’s U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 16, 2020.All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.